EXPERT VIEW

TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS

Mark Parry, John McLaughlin and Tino Otte discuss the necessary studies required to understand the nitrosamine formation and leachables profiles of new pMDI propellants with lower global warming potentials as part of the pharmaceutical industry’s drive to reduce its emissions and environmental impact.

ENVIRONMENTAL BENEFITS OF BEDSIDE IONIC NITRIC OXIDE GENERATION

David Webster and Mark Rimkus consider the environmental impact of traditional high-pressure storage systems for nitric oxide and highlight the benefits associated with bedside ionic generation.

FUTURE TRENDS FOR NOVEL INJECTABLE DRUG DELIVERY

Chris Hurlstone

FUTURE TRENDS FOR NOVEL INJECTABLE DRUG DELIVERY

Chris Hurlstone looks at the increasing demand for novel injectable devices and summarises the areas we can expect to see significant development activities in injectable technologies.

DEFINING HIGH-VISCOSITY, LARGE-VOLUME DRUG DELIVERY SYSTEMS

DEFINING HIGH-VISCOSITY, LARGE-VOLUME DRUG DELIVERY SYSTEMS

Kyle Toole, Blair Hutton and James McLusky discuss the value that mathematical modelling can provide in the early stages of injectable drug delivery device development, especially when coupled with appropriate empirical testing in a laboratory setting.

NAVIGATING THE AI REVOLUTION IN THE MEDICAL DEVICES SECTOR: BETWEEN INNOVATION AND REGULATION

NAVIGATING THE AI REVOLUTION IN THE MEDICAL DEVICES SECTOR: BETWEEN INNOVATION AND REGULATION

Timothy Bubb discusses the potential impact of artificial intelligence and machine learning on the healthcare and drug delivery industries, with an overview of the differing regulatory approaches taken by the EU, US FDA and UK MHRA towards this novel area of digital health.

SUSTAINABLE DESIGN FOR HEALTHCARE DEVICES: PATHWAYS TOWARDS NET ZERO

SUSTAINABLE DESIGN FOR HEALTHCARE DEVICES: PATHWAYS TOWARDS NET ZERO

Will Davies and Holly Milston consider sustainable pathways towards circularity in the medical device industry.

THE SPECIFIC APPROACH: THE ADVANTAGE OF CUSTOMISATION FOR WEARABLE DELIVERY SYSTEMS

Dave Beckstoffer

THE SPECIFIC APPROACH: THE ADVANTAGE OF CUSTOMISATION FOR WEARABLE DELIVERY SYSTEMS

Dave Beckstoffer considers how involving customisation from the outset of an on-body injector development project can not only optimise the patient outcome but also streamline the development timescale for device engineers, with a particular focus on the drive system.

MATERIAL SELECTION & EFFICIENT DEVELOPMENT PROCESSES FOR WEARABLE INJECTOR DRIVE SYSTEMS

Dave Beckstoffer

MATERIAL SELECTION & EFFICIENT DEVELOPMENT PROCESSES FOR WEARABLE INJECTOR DRIVE SYSTEMS

Dave Beckstoffer explains the importance of material selection in drive system development, the key attributes of materials towards a wearable and auto-delivery device, and discusses the need to achieve industrialisation based on material selection and relevant manufacturing processes.

USING EFFICIENT PROOF-OF-CONCEPT TESTS AND PILOT MOULDS FOR DEVICE DEVELOPMENT SUCCESS

USING EFFICIENT PROOF-OF-CONCEPT TESTS AND PILOT MOULDS FOR DEVICE DEVELOPMENT SUCCESS

Andreas Wild and Andreas Montag discuss the value of early proof-of-concept testing and sample production for drug delivery device development projects, with an emphasis on how partnership and consultation can smooth and enhance this process, including for design for automation and design for manufacturing considerations.

CLOSING THE LOOP: THE LATEST ON ARTIFICIAL PANCREAS SYSTEMS

Kamaal de Silva

CLOSING THE LOOP: THE LATEST ON ARTIFICIAL PANCREAS SYSTEMS

Kamaal de Silva looks at the future of closed-loop insulin delivery systems and how the management of Type 1 diabetes is developing in the digital era.

ADAPTING TO AN AGEING WORLD: FORMULATION STRATEGIES TO BOOST PATIENT COMPLIANCE

ADAPTING TO AN AGEING WORLD: FORMULATION STRATEGIES TO BOOST PATIENT COMPLIANCE

Jason Hunt and Yeli Zhang discuss the key factors undermining patient compliance in older adults and explore how the pharmaceutical industry can leverage excipients to enhance drug formulations and improve medication compliance among this critical demographic.

ARE ORAL FORMULATIONS OF OLIGONUCLEOTIDE THERAPEUTICS WITHIN REACH?

ARE ORAL FORMULATIONS OF OLIGONUCLEOTIDE THERAPEUTICS WITHIN REACH?

Nigel Theobald, discusses key issues and strategies for formulation scientists aiming to unlock the potential of oral delivery for small interfering ribonucleic acid drugs targeted against gastrointestinal diseases and cancers.

DIFFERENTIATING ORAL SUSPENSIONS WITH VERSATILE EXCIPIENTS

Mariona Venceslao Molins

DIFFERENTIATING ORAL SUSPENSIONS WITH VERSATILE EXCIPIENTS

Mariona Venceslao Molins and Liliana Miinea discuss how excipient-based approaches can facilitate patient-centric formulations and transform oral suspensions.

STRATEGIES TO MITIGATE GELATIN CROSS-LINKING IN ORAL SOLID DRUG DELIVERY

Dr Jnanadeva Bhat

STRATEGIES TO MITIGATE GELATIN CROSS-LINKING IN ORAL SOLID DRUG DELIVERY

Jnanadeva Bhat and Manali Dalvi discuss the factors contributing to gelatin cross-linking in oral solid dose delivery – and strategies to tackle the resulting challenges.

CANNABIDIOL DELIVERY THAT IS ON THE “TIP OF THE TONGUE”

Dr Zdravka Misic

CANNABIDIOL DELIVERY THAT IS ON THE “TIP OF THE TONGUE”

Zdravka Misic explores how formulation expertise can be applied to overcome the low bioavailability of cannabinoids and how innovation in orally disintegrating tablets is driving progress for cannabidiol-based therapeutics.

THROUGH THICK AND THIN: MODELLING THE DELIVERY OF NON-NEWTONIAN FORMULATIONS

THROUGH THICK AND THIN: MODELLING THE DELIVERY OF NON-NEWTONIAN FORMULATIONS

Alex Vasiev explores the challenges inherent in understanding flow rates in injectable drug delivery when dealing with non-Newtonian fluids, and provides an overview of how to calculate flow rates for power law, Carreau and Cross fluids.

ACCELERATING COMBINATION PRODUCT DEVELOPMENT USING DIGITAL TWIN TECHNOLOGY

ACCELERATING COMBINATION PRODUCT DEVELOPMENT USING DIGITAL TWIN TECHNOLOGY

Dan Cowen, Sebastian White and Anthony Robinson, discuss the value that implementing a digital twin could provide to drug delivery device design across multiple stages of a development programme.

SUSTAINABLE BY DESIGN: DEVELOPING PATIENT- AND PLANET-CENTRIC MEDICAL DEVICES

SUSTAINABLE BY DESIGN: DEVELOPING PATIENT- AND PLANET-CENTRIC MEDICAL DEVICES

Su Osorio, Stephanie Mou and Charlie Dean, explore the delicate balance between patient and planet centricity and propose a user- and planet-centric approach for the development of sustainable medical devices.

NAVIGATING THE TRANSITION TO SUSTAINABLE MEDICAL PROPELLANTS

Dr Timothy Noakes

NAVIGATING THE TRANSITION TO SUSTAINABLE MEDICAL PROPELLANTS

Timothy Noakes, Sheryl Johnson and Richard Greenhough, discuss the status of the current move from high-global-warming-potential propellants for pressurised metered dose inhalers to more sustainable alternatives.

CHANGE IS IN THE AIR: THE FUTURE CLIMATE OF INHALED MEDICATION

Pauline Janssen

CHANGE IS IN THE AIR: THE FUTURE CLIMATE OF INHALED MEDICATION

Pauline Janssen, discusses the various available devices for pulmonary delivery of medications, with a deeper dive into the challenges presented by replacing pMDI propellants with high global warming potential with new alternatives, or whether the optimal solution could be phasing out pMDIs in favour of DPIs.

PHARMACEUTICAL INDUSTRY SUSTAINABILITY TARGETS, ONE YEAR ON

Catriona Eldridge

PHARMACEUTICAL INDUSTRY SUSTAINABILITY TARGETS, ONE YEAR ON

Catriona Eldridge, analyses whether the pharmaceutical industry is meeting its targets and doing enough in the fight against climate change.

REUSABLE VERSUS SINGLE-USE DEVICES: TRADE-OFFS IN IMPROVING SUSTAINABILITY

Alastair Willoughby

REUSABLE VERSUS SINGLE-USE DEVICES: TRADE-OFFS IN IMPROVING SUSTAINABILITY

Alastair Willoughby and Prem-Sagar Tank, explore various device trade-offs for both sustainability and cost in reusable injection devices, and consider how this compares with single-use devices.

SCALING GLP-1 DRUGS WITHOUT A MOUNTAIN OF WASTE

SCALING GLP-1 DRUGS WITHOUT A MOUNTAIN OF WASTE

Matt Parker, Simon Lyons and Alex Lyness, look at how the continued success of glucagon-like peptide-1 drugs is bringing into focus the need for environmentally sustainable self-injection systems. They discuss whether reloadable autoinjectors could be the way to boost sustainability, lower cost per dose, and match the scale and rate of adoption of these new therapies.

SOFT MIST INHALERS VERSUS NEBULISERS: DELIVERY EQUIVALENCE & FUTURE THERAPIES

SOFT MIST INHALERS VERSUS NEBULISERS: DELIVERY EQUIVALENCE & FUTURE THERAPIES

Zaid Aqrawe, Philippe Rogueda, Darragh Murnane and Bryan Eng, discuss the opportunity presented by soft mist inhalers as an alternative delivery device to nebulisers for inhaled therapies, contrasting the two device categories across multiple factors.

BUBBLE-WRAPPED REMEDIES: HOW LIPID-ENCASED THERAPEUTICS COULD TRANSFORM INHALATION

Dr Ethan Miller

BUBBLE-WRAPPED REMEDIES: HOW LIPID-ENCASED THERAPEUTICS COULD TRANSFORM INHALATION

Ethan Miller and Heather Jameson shed light on some of the intricacies that lipid-encapsulated therapeutics bring to the realm of inhalation therapies, and some considerations on how the type of inhalation device selected may help to mitigate issues around formulation stability and efficient delivery to target cells.

HOW TO CHOOSE THE RIGHT INTRANASAL VACCINE DEVICE

HOW TO CHOOSE THE RIGHT INTRANASAL VACCINE DEVICE

Nia Stevens, discusses the potential benefits of developing vaccines for intranasal administration with a suitable drug delivery device, as well as the challenges associated with this delivery route.

1
2
3
…
12
Next

Top